MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on December 21, 2007; DOI: 10.1124/mol.107.044586

0026-895X/08/7303-616-618$20.00
Mol Pharmacol 73:616-618, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Artcle
Right arrow All Versions of this Article:
mol.107.044586v1
mol.107.044586v2
mol.107.044586v3
mol.107.044586v4
73/3/616    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Henry, L. K.
Right arrow Articles by Blakely, R. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henry, L. K.
Right arrow Articles by Blakely, R. D.
Perspective

Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend

L. Keith Henry, and Randy D. Blakely

Departments of Pharmacology (L.K.H., R.D.B.) and Psychiatry (R.D.B.), Centers for Structural Biology (L.K.H.) and Molecular Neuroscience (R.D.B.), Vanderbilt University, Nashville, Tennessee

Abuse of psychostimulants such as cocaine and amphetamines has a tremendous social and economic impact. Although replacement therapies are offered for addiction to opioids, nicotine, and alcohol, there is no approved replacement treatment for psychostimulant addiction. Recent studies on an emerging group of benztropine- and rimcazole-based compounds provide hope that replacement therapies for cocaine and amphetamine addiction may come in the near future. A new study (p. 813) now investigates the molecular interaction of the benztropine and rimcazole compounds with their target, the dopamine transporter, and provides an intriguing explanation as to why use of these compounds, unlike cocaine, do not lead to locomotor stimulation and drug discrimination behaviors in animal models.

Received December 21, 2007; accepted December 21, 2007

Address correspondence to: Dr. L. Keith Henry, Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58203. E-mail: khenry{at}medicine.nodak.edu


Related articles in MolPharm:

Relationship between Conformational Changes in the Dopamine Transporter and Cocaine-Like Subjective Effects of Uptake Inhibitors
Claus J. Loland, Rajeev I. Desai, Mu-Fa Zou, Jianjing Cao, Peter Grundt, Klaus Gerstbrein, Harald H. Sitte, Amy Hauck Newman, Jonathan L. Katz, and Ulrik Gether
MolPharm 2008 73: 813-823. [Abstract] [Full Text]  





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics